648 related articles for article (PubMed ID: 17960794)
1. Aberrant methylation of E-cadherin and H-cadherin genes in nonsmall cell lung cancer and its relation to clinicopathologic features.
Kim DS; Kim MJ; Lee JY; Kim YZ; Kim EJ; Park JY
Cancer; 2007 Dec; 110(12):2785-92. PubMed ID: 17960794
[TBL] [Abstract][Full Text] [Related]
2. Aberrant methylation of H-cadherin (CDH13) promoter is associated with tumor progression in primary nonsmall cell lung carcinoma.
Kim JS; Han J; Shim YM; Park J; Kim DH
Cancer; 2005 Nov; 104(9):1825-33. PubMed ID: 16177988
[TBL] [Abstract][Full Text] [Related]
3. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
[TBL] [Abstract][Full Text] [Related]
4. Aberrant promoter methylation of multiple genes in non-small cell lung cancers.
Zöchbauer-Müller S; Fong KM; Virmani AK; Geradts J; Gazdar AF; Minna JD
Cancer Res; 2001 Jan; 61(1):249-55. PubMed ID: 11196170
[TBL] [Abstract][Full Text] [Related]
5. Hypermethylation of E-cadherin gene is frequent and independent of p16INK4A methylation in non-small cell lung cancer: potential prognostic implication.
Shimamoto T; Ohyashiki JH; Hirano T; Kato H; Ohyashiki K
Oncol Rep; 2004 Aug; 12(2):389-95. PubMed ID: 15254707
[TBL] [Abstract][Full Text] [Related]
6. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance.
Nakata S; Sugio K; Uramoto H; Oyama T; Hanagiri T; Morita M; Yasumoto K
Cancer; 2006 May; 106(10):2190-9. PubMed ID: 16598757
[TBL] [Abstract][Full Text] [Related]
7. Hypermethylation of FHIT as a prognostic marker in nonsmall cell lung carcinoma.
Maruyama R; Sugio K; Yoshino I; Maehara Y; Gazdar AF
Cancer; 2004 Apr; 100(7):1472-7. PubMed ID: 15042681
[TBL] [Abstract][Full Text] [Related]
8. Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer.
Kim H; Kwon YM; Kim JS; Lee H; Park JH; Shim YM; Han J; Park J; Kim DH
J Clin Oncol; 2004 Jun; 22(12):2363-70. PubMed ID: 15197197
[TBL] [Abstract][Full Text] [Related]
9. Promoter-hypermethylation associated defective expression of E-cadherin in primary non-small cell lung cancer.
Wang G; Hu X; Lu C; Su C; Luo S; Luo ZW
Lung Cancer; 2008 Nov; 62(2):162-72. PubMed ID: 18468719
[TBL] [Abstract][Full Text] [Related]
10. Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas.
Toyooka KO; Toyooka S; Virmani AK; Sathyanarayana UG; Euhus DM; Gilcrease M; Minna JD; Gazdar AF
Cancer Res; 2001 Jun; 61(11):4556-60. PubMed ID: 11389090
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic inactivation of Homeobox A5 gene in nonsmall cell lung cancer and its relationship with clinicopathological features.
Kim DS; Kim MJ; Lee JY; Lee SM; Choi JY; Yoon GS; Na YK; Hong HS; Kim SG; Choi JE; Lee SY; Park JY
Mol Carcinog; 2009 Dec; 48(12):1109-15. PubMed ID: 19554572
[TBL] [Abstract][Full Text] [Related]
12. Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma.
Hsu HS; Chen TP; Hung CH; Wen CK; Lin RK; Lee HC; Wang YC
Cancer; 2007 Nov; 110(9):2019-26. PubMed ID: 17876837
[TBL] [Abstract][Full Text] [Related]
13. Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival.
Brabender J; Usadel H; Danenberg KD; Metzger R; Schneider PM; Lord RV; Wickramasinghe K; Lum CE; Park J; Salonga D; Singer J; Sidransky D; Hölscher AH; Meltzer SJ; Danenberg PV
Oncogene; 2001 Jun; 20(27):3528-32. PubMed ID: 11429699
[TBL] [Abstract][Full Text] [Related]
14. [Detection of free tumor-related DNA in the serum of breast cancer patients].
Zhang JJ; Ouyang T; Wan WH; Deng GR
Zhonghua Zhong Liu Za Zhi; 2007 Aug; 29(8):609-13. PubMed ID: 18210882
[TBL] [Abstract][Full Text] [Related]
15. p16INK4A and CDH13 hypermethylation in tumor and serum of non-small cell lung cancer patients.
Ulivi P; Zoli W; Calistri D; Fabbri F; Tesei A; Rosetti M; Mengozzi M; Amadori D
J Cell Physiol; 2006 Mar; 206(3):611-5. PubMed ID: 16222700
[TBL] [Abstract][Full Text] [Related]
16. Elevated mRNA levels of DNA methyltransferase-1 as an independent prognostic factor in primary nonsmall cell lung cancer.
Kim H; Kwon YM; Kim JS; Han J; Shim YM; Park J; Kim DH
Cancer; 2006 Sep; 107(5):1042-9. PubMed ID: 16888795
[TBL] [Abstract][Full Text] [Related]
17. Quantitative promoter hypermethylation analysis of cancer-related genes in salivary gland carcinomas: comparison with methylation-specific PCR technique and clinical significance.
Lee ES; Issa JP; Roberts DB; Williams MD; Weber RS; Kies MS; El-Naggar AK
Clin Cancer Res; 2008 May; 14(9):2664-72. PubMed ID: 18451230
[TBL] [Abstract][Full Text] [Related]
18. Can aberrant promoter hypermethylation of CpG islands predict the clinical outcome of non-small cell lung cancer after curative resection?
Kim YT; Lee SH; Sung SW; Kim JH
Ann Thorac Surg; 2005 Apr; 79(4):1180-8; discussion 1180-8. PubMed ID: 15797047
[TBL] [Abstract][Full Text] [Related]
19. Long interspersed nuclear element 1 hypomethylation is a marker of poor prognosis in stage IA non-small cell lung cancer.
Saito K; Kawakami K; Matsumoto I; Oda M; Watanabe G; Minamoto T
Clin Cancer Res; 2010 Apr; 16(8):2418-26. PubMed ID: 20371677
[TBL] [Abstract][Full Text] [Related]
20. CpG hypermethylation of promoter region and inactivation of E-cadherin gene in human bladder cancer.
Ribeiro-Filho LA; Franks J; Sasaki M; Shiina H; Li LC; Nojima D; Arap S; Carroll P; Enokida H; Nakagawa M; Yonezawa S; Dahiya R
Mol Carcinog; 2002 Aug; 34(4):187-98. PubMed ID: 12203370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
